Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations

Asian Pacific Journal of Allergy and Immunology

Volumn 27, Issue 4, 2009, Pages 209-216

  Promsuwicha, Orathai ^a   Auewarakul, Chirayu U ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; SENSITIVITY AND SPECIFICITY; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETICS; IMMUNOLOGY; KARYOTYPING; METABOLISM; PREDICTION AND FORECASTING; RECURRENT DISEASE;

ANTIGENS, CD34; CELL SEPARATION; DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; GENOME-WIDE ASSOCIATION STUDY; HLA-DR ANTIGENS; HUMANS; KARYOTYPING; LEUKEMIA, PROMYELOCYTIC, ACUTE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TRANSLOCATION, GENETIC;

EID: 77953623074     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-907.
2. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976-82.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neop-lasms. Blood 2002; 100: 2292-302.
4. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-67.
5. Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry A 2004; 58: 62-71.
6. Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003; 17: 515-27.
7. Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003; 127: 42-8.
8. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Clin Haematol 2003; 16: 369-85.
9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-8.
10. Lewis RE, Cruse JM, Webb RN, Sanders CM, Beason K. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias. Exp Mol Pathol 2007; 83: 269-73.
11. Mitelman F. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karker; 1995.
12. Auewarakul CU, Promsuwicha O, U-Pratya Y, Pattanapa-nyasat K, Issaragrisil S. Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol 2003; 21: 153-60.
13. Auewarakul CU, Lauhakirti D, Promsuwicha O, Munkhetvit C. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive values in the diagnosis of Thai adult acute myeloid leukemia. Ann Hematol 2006; 85: 108-12.
14. Straus SE, Scott Richardson W, Glasziou P, Brian Haynes R. Evidence-based Medicine: how to practice and teach EBM. London: Elsevier Churchill Livingstone; 2005.
15. Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003; 17: 707-15.
16. Lazarchick J, Hopkins M. HLA-DR negative acute non-lymphocytic leukemia. Ann Clin Lab Sci 1998; 28: 150-2.
17. Basso G, Lanza F, Orfao A, Moretti S, Castoldi G. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents 2001; 15: 68-78.
18. Ferrara F, Di Noto R, Annunziata M, et al. Immunopheno-typic analysis enables the correct prediction of t(8;21) in acute myeloid leukaemia. Br J Haematol 1998; 102: 444-8.
19. Khoury H, Dalal BI, Nevill TJ, et al. Acute myelogenous leukemia with t(8;21)- identification of a specific immuno-phenotype. Leuk Lymphoma 2003; 44: 1713-8.
20. Syampurnawati M, Tatsumi E, Furuta K, et al. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res 2007; 31: 921-9.
21. Syampurnawati M, Tatsumi E, Ardianto B, et al. DR nega-tivity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. Leuk Res 2008; 32: 1141-3.
22. Lee JJ, Cho D, Chung IJ, et al. CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. Am J Hematol 2003; 73: 149-53.
23. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004; 28: 43-8.
24. Webber BA, Cushing MM, Li S. Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. Int J Clin Exp Pathol 2008; 1: 124-33.